Expectancies as predictors of symptom improvement after antimicrobial therapy for persistent symptoms attributed to Lyme disease

Henriët van Middendorp1 · Anneleen Berende2,3 · Fidel J. Vos2,4 · Hadewych H. M. ter Hofstede2 · Bart Jan Kullberg2 · Andrea W. M. Evers1,5

Received: 20 December 2020 / Revised: 29 April 2021 / Accepted: 2 May 2021 / Published online: 24 May 2021 © The Author(s) 2021

Abstract

Introduction/Objective Expectancies about symptom improvement or deterioration are reliable predictors of symptom progression and treatment outcomes (symptom resolution or symptomatic improvement) in many (non-)pharmacological studies and treatments. This study examined predictors of symptom improvement after antimicrobial therapy for persistent symptoms attributed to Lyme disease, hypothesizing particularly pre-treatment expectancies regarding symptom improvement to be predictive.

Methods A predictive study was performed on pre-treatment and post-treatment individual characteristics, including expectancies, and physical and mental health–related quality of life (HRQoL) from the PLEASE-trial comparing randomized 12-weeks of doxycycline, clarithromycin-hydroxychloroquine, or placebo following 2 weeks of intravenous ceftriaxone. At end-of-treatment (14 weeks after trial start) and follow-up (52 weeks), complete data of 231 and 170 (of initial 280) patients with persistent symptoms temporally related to a history of erythema migrans or otherwise confirmed symptomatic Lyme disease, or accompanied by B. burgdorferi IgG or IgM antibodies, were examined through hierarchical regression analyses.

Results In addition to pre-treatment HRQoL, pre-treatment expectancies regarding symptom improvement were consistently associated with stronger physical and mental HRQoL improvements at both end-of-treatment and follow-up (95% CI range: .09;.54, p < .01 to .27;.92, p < .001). Post-treatment expectancies regarding having received antibiotics vs. placebo was associated with more HRQoL improvement at end-of-treatment, but not at follow-up (95% CI-range 1.00;4.75, p = .003 to −7.34;−2.22, p < .001).

Conclusions The present study shows that, next to pre-treatment functioning, patients’ pre-treatment and post-treatment expectancies regarding persistent symptoms attributed to Lyme disease relate to a more beneficial symptom course. Expectancies of patients may be relevant to explain and potentially improve patient outcomes (e.g., by optimized communication about treatment success).

Trial registration ClinicalTrials.gov, NCT01207739 (Registration date: 23–09-2010)

Key Points

• As there is currently no sufficient symptom resolution or symptomatic improvement for many patients with persistent symptoms attributed to Lyme disease, it is relevant to know which factors determine symptom progression and predict heterogeneity in treatment response.

• Next to pre-treatment functioning, expectancies regarding symptom improvement and having received antimicrobial study medication are associated with a more beneficial symptom course after both shorter-term and longer-term antimicrobial treatment.

• Expectancies are relevant to consider in treatment studies and may be useful in clinical settings to improve symptom course and treatment outcome (e.g., by optimized communication about treatment success).

Keywords Antibiotics treatment · Expectancies · Lyme disease · Psychology · Treatment outcome

Introduction

Large numbers of patients present with persistent symptoms attributed to infection with Borrelia burgdorferi [1, 2]. These patients mainly experience disabling symptoms of...
pain, fatigue, and neurological and cognitive disturbances. The most commonly provided current medical treatment consists of either shorter-term (2–4 weeks) or longer-term (≥3 months) antimicrobial therapy. Previous studies have indicated that, despite positive outcomes for a subset of patients, current standardized protocols of shorter-term and longer-term antimicrobial therapies do not offer a sufficient symptom resolution or symptomatic improvement for many patients with persistent symptoms [3–6]. Thus, it is relevant to know which factors determine symptom progression and predict heterogeneity in treatment response, as this could offer potential new ways to individualize treatment and improve patient outcomes for a larger patient group.

Various demographic, disease-related, and individual characteristics, as well as pre-treatment functioning, have been related to treatment outcomes (symptom resolution or symptomatic improvement) in previous studies in diverse populations, including patients with persistent symptoms attributed to Lyme disease. However, the results were inconsistent, limiting the clinical implications of these findings [7–13]. More recently, particular interest has been devoted to the role of expectancies of patients regarding their symptom progression and treatment outcomes. In many placebo-controlled trials, expectancies are reliable predictors of treatment outcomes in a broad variety of pharmacological and non-pharmacological treatments [14–20]. Moreover, some studies have shown that the drug that patients thought they received (active or placebo) was more strongly related to outcome than the actual drug received [21, 22]. As increasingly acknowledged and starting to be applied in clinical populations [23–28], expectancies may thus strengthen or even partly determine the effects of these treatments.

The current study examines the role of pre-treatment and post-treatment expectancies in comparison to other individual characteristics in predicting primary outcomes of symptom improvement after antimicrobial therapy for persistent symptoms attributed to Lyme disease. We hypothesized that, in addition to pre-treatment functioning, particularly pre-treatment expectancies regarding symptom improvement would be predictive of changes in physical and mental health-related quality of life (HRQoL) immediately after treatment and at the longer term.

Materials and methods

Participants and procedure

The current study concerns a secondary analysis of the data collected as part of the Persistent Lyme Empiric Antibiotic Study Europe (PLEASE) [3], a multicentre, placebo-controlled, double-blind randomized controlled trial conducted at two tertiary health centers in the Netherlands, the Radboud University Medical Center and the Sint Maartenskliniek. The PLEASE study examined whether two specific standardized longer-term antimicrobial therapies would lead to better patient outcomes than a 2-week standardized shorter-term antimicrobial therapy followed by placebo in patients with symptoms attributed to Lyme disease. The trial was registered at ClinicalTrials.gov (NCT01207739) and its design and main results have been reported in previous papers [3, 29]. In short, 280 patients with persistent symptoms (e.g., pain, musculoskeletal symptoms, neuralgia, sensory disturbances, neuropsychological complaints, fatigue) that were either temporally related to a history of an erythema migrans (EM) or otherwise confirmed symptomatic Lyme disease, or accompanied by B. burgdorferi IgG or IgM antibodies were included into the trial. All participants received 2000-mg open-label intravenous ceftriaxone daily for 2 weeks (shorter-term treatment) before starting a blinded oral antibiotic regimen of 12 weeks (longer-term treatment), for which they were randomly allocated in a 1:1:1 ratio to one of three treatment arms: (1) 100 mg of doxycycline twice daily plus placebo twice daily; (2) 500 mg clarithromycin twice daily plus 200 mg hydroxychloroquine twice daily; or (3) two placebos twice daily. The data for the current study were derived from questionnaires assessed at study start, at 14 weeks (end-of-treatment; primary outcome assessment point) and 52 weeks (long-term follow-up) after study start. The study was ethically approved by the Medical Ethics Review Committee CMO Region Arnhem-Nijmegen, and all participants gave written informed consent.

Instruments

Primary and secondary outcome measures

The same primary and secondary physical and mental health–related quality of life (HRQoL) outcome measures as in the PLEASE trial [3] were examined in this study.

Physical HRQoL

Physical component summary score As primary outcome, the physical component summary score (PCS) of the RAND-36 Health Status Inventory (RAND SF-36) was assessed [30]. This score is calculated as norm-based T-score from the four weighted physical subscales (physical functioning, role limitations due to physical health problems, pain, and general health perceptions); these T-scores range from 15 to 61 and have a mean of 50 and standard deviation of 10 in the general population, with higher scores indicating a better physical HRQoL.

Fatigue severity Fatigue, which is a frequent symptom that is not measured within the PCS of the RAND SF-36, was assessed as a secondary outcome by means of the severity of fatigue subscale of the Checklist Individual Strength (CIS) [31]. This is an 8-item scale with a score range of 8 to 56, with a mean of 17 and
a standard deviation of 10 in a healthy sample. Higher scores on this measure indicate more severe fatigue.

**Mental HRQoL**

**Mental component summary score** As another secondary outcome, the mental component summary score (MCS) of the RAND SF-36 [30] was assessed, calculated as norm-based T-scores ($M=50$, $SD=10$ in the general population) from the four weighted mental subscales (emotional well-being, role limitations due to emotional problems, social functioning, and energy). The T-scores on this measure range from 11 to 66, with higher scores indicating a better mental HRQoL.

**Predictors of symptom improvement after antimicrobial therapy**

Three categories of predictor variables were assessed: (1) demographic, disease-related, and study-related characteristics; (2) pre-treatment functioning; and (3) individual characteristics, including expectancies.

**Demographic, disease-related, and study-related characteristics**

The following demographic characteristics were assessed pre-treatment: age, sex, marital status, education level, smoking, and paid labor. Disease-related factors assessed pre-treatment were duration of symptoms attributed to Lyme disease and use of pain medication at start of study. The study-related factor included was the randomized treatment arm (doxycycline, clarithromycin plus hydroxychloroquine, or placebo).

**Pre-treatment functioning**

Pre-treatment scores on the primary and secondary outcome measures of physical and mental HRQoL were assessed before randomization and trial-treatment.

**Individual characteristics**

The following variables were assessed at pre-treatment as possible predictors of the treatment outcome:

**Pre-treatment expectancies regarding symptom improvement** To evaluate expectancies on symptom progression, six items assessed the degree to which participants expected that their symptoms would disappear in the upcoming period (e.g., “I think that my complaints will totally disappear during the upcoming 6 months” and “I think that I will no longer need any medical help for my complaints in the future”), in line with previous studies [18, 32]. Items could be answered on a 4-point Likert scale, varying from 1 “largely disagreed” to 4 “largely agreed,” with a sum score between 6 and 24. A higher score indicates higher expectancies of improvement regarding the course of symptoms. The internal consistency (Cronbach’s alpha = 0.88) was good.

**Self-efficacy** To determine self-efficacy, six statements on arthritis self-efficacy [33] were adapted to a Lyme Self-Efficacy (LSE) scale, in which the word “pain” was replaced with “physical symptoms” (e.g., “I am certain that I can control my physical symptoms”). Items are answered on a 1 (“totally disagree”) to 5 (“totally agree”) Likert scale, summing up to a score between 6 and 30, with higher scores indicating more self-efficacy. Cronbach’s alpha was 0.78.

**Illness cognitions** The illness cognitions of helplessness (e.g., “Because of my illness I miss the things I like to do most”), acceptance (“I have learned to accept the limitations imposed by my illness”), and perceived benefits (“Dealing with my illness has made me a stronger person”) were assessed by means of three 6-item scales of the Illness Cognition Questionnaire (ICQ) [34]. Items are answered on a 1 (“not at all”) to 5 (“completely”) Likert scale, adding up to a score between 6 and 24, with higher scores indicating higher levels of helplessness, acceptance, or perceived benefits, respectively. Cronbach’s alphas were 0.87 for helplessness and acceptance, and 0.84 for perceived benefits.

**Worrying** To assess worrying, the Penn-State Worry Questionnaire (PSWQ) [35] was used, including 14 statements (e.g., “I know I shouldn’t worry about things, but I just can’t help it”) measuring the tendency, intensity, and uncontrollability of worrying on a scale of 1 (“not at all typical of me”) to 5 (“very typical of me”). Higher scores indicate more worrying. Cronbach’s alpha was 0.93.

**Personality** By means of the Eysenck Personality Questionnaire [36], neuroticism (22 items, e.g., “Does your mood often go up and down?”) and extraversion (19 items, e.g., “Do you enjoy meeting new people?”) were assessed by means of yes/no answers. Higher scores indicate more neuroticism and extraversion, and Cronbach’s alphas were 0.87 and 0.86, respectively.

Post-treatment, one additional expectancy variable was assessed:

**Post-treatment expectancies of presumed study medication** At the end-of-treatment (week 14), when returning the study medication bottles, participants were asked what medication they thought they had received, with answering options “antibiotics,” “placebo,” or “do not know.” To make this factor analyzable in regression equations, the variable was converted into “antibiotics” (score 1) or “placebo/don’t know” (score 0).
Data analysis

To have comparable analyses across outcome measures per assessment point, analyses were performed on complete data sets of all predictor and outcome measures, leading to a sample of 231 patients at end-of-treatment and 170 at follow-up. Descriptive statistics were computed, and changes in HRQoL between the different assessment points were assessed by means of paired-samples t-tests. To determine which factors could potentially impact quality of life change, zero-order associations of demographic, disease-related, study-related, and individual characteristics with the outcome measures at week 14 and 52, controlled for pre-treatment HRQoL, were examined by means of analyses of covariance (categorical characteristics) or partial correlations (continuous characteristics). Sex, age, use of pain medication, and acceptance (of the ICQ) did not show significant zero-order associations with any of the quality of life changes in outcome measures at end-of-treatment or follow-up. This held both in the total group and in separate analyses for the two combined longer-term treatment arms and the shorter-term followed by placebo treatment arm. Also, in line with the main results of the PLEASE-trial [3], the treatment arm was not associated with any of the quality of life changes in outcome measures, also when the two longer-term treatment arms were combined (all p-values ≥0.37). Therefore, these variables were not included in the regression analyses, with the main analyses being conducted in the total group, followed by sensitivity analyses for the shorter-term treatment arm and the combined longer-term treatment arms.

To examine the relative contribution of expectancies and other individual characteristics on physical and mental HRQoL after antimicrobial therapy, separate hierarchical regression analyses were conducted per outcome measure (PCS, fatigue, MCS). In the first block, demographic, disease-related, and study-related characteristics were included. In the second block, the pre-treatment score of the outcome measure was included to control for cross-sectional variance with the other predictor variables, enabling the prediction of changes in HRQoL from pre-treatment to end-of-treatment or follow-up. In the third block, individual characteristics were entered. In order to ensure the most parsimonious model testing was performed with only those predictor variables that showed at least one significant predictive association across all regression analyses.

To examine whether post-treatment expectancies regarding presumed study medication were related more strongly to HRQoL improvements than actual treatment allocation, analyses of covariance were conducted for treatment allocation with both longer-term treatments combined and with presumed antibiotic study medication per outcome measure (PCS, fatigue, MCS at both end-of-treatment and follow-up), including sex and baseline HRQoL as covariates in line with the analyses performed on the PLEASE trial [3]. Although the power analysis was based on the main research question of the PLEASE-trial [3], the smallest sample size of 170 patients indicated adequate power according to the rule of thumb of at least 10 participants per predictor variable [37]. All analyses were conducted with SPSS 25 and significance was accepted at p < 0.05.

Results

Descriptive statistics

The antibiotic treatment itself showed a very low drop-out, with 90% of randomized participants (252) completing the oral regimen of active study drug or placebo. In order to optimize comparability between analyses, for the current research questions, only those participants were included who had complete data with regard to all variables included in the study at either the end-of-treatment or the follow-up time point. Thus, this led to a total of 231 complete data sets at end-of-treatment and 170 at follow-up (66 drop-outs between baseline and follow-up and 5 inclusions at follow-up only, because of missed outcome values at end-of-treatment).

Table 1 depicts the demographic, disease-related, and study-related characteristics, and baseline, end-of-treatment, and follow-up scores on the primary and secondary outcome measures, and baseline scores on the pre-treatment individual characteristics of the patients with complete end-of-treatment or follow-up data. The patients who did not complete all measures included at follow-up (n = 61) did not differ on most variables from the completer sample (n = 170), including all HRQoL measures, but were somewhat younger (p=0.001) and had an overall lower acceptance (p=0.04) and higher extraversion level (p=0.001) than the completer sample. More specific information on the completer versus non-completer samples at both time points can be found in Appendix Tables 4 and 5.

Across groups, all quality of life outcome measures showed significant HRQoL improvements from pre-treatment to end-of-treatment (14 weeks; all p-values <0.001), with further improvement (physical component summary score, p=0.02) or stabilization of the improvement (fatigue, p=0.09; mental component summary score, p=0.46) at follow-up (52 weeks). Differentiating longer-term versus shorter-term treatment showed similar findings for fatigue and mental HRQoL, and a continued improvement vs. stabilization in the physical component summary score in the combined longer-term treatment arms vs. the shorter-term treatment arm (p=0.045 vs. 0.19). In Appendix 1, the associations between the pre-treatment individual characteristics and demographic and disease-related factors are described.

Pre-treatment predictors of quality of life course

Table 2 shows the main results of the hierarchical regression analyses in the total group examining the prediction of quality
of life course after antimicrobial therapy based on those pre-treatment variables that correlated with the HRQoL at end-of-treatment (14 weeks) or follow-up (52 weeks). Having a partner, education level, duration of symptoms attributed to Lyme disease, helplessness, disease benefits, and extraverion did not significantly add to explaining the variance in any of the outcome measures. Therefore, to present the most parsimonious model, these variables were excluded from the final regression models.

For all physical and mental HRQoL measures, each separate block of pre-treatment demographic characteristics, pre-treatment functioning, and pre-treatment individual characteristics significantly added explained variance to the model, with a total explained variance between 40 and 56%, depending on the outcome measure. The largest amount of variance (27–40%) was explained by pre-treatment functioning on that particular outcome measure. The demographic characteristics paid labor (predicting better physical and mental HRQoL) and smoking (predicting worse mental HRQoL, mainly at follow-up) added 5 to 12%. The pre-treatment individual characteristics added 5 to 11% to the explained variance (Table 2).

In the total group, pre-treatment expectancies regarding symptom improvement consistently predicted physical and mental HRQoL at end-of-treatment on top of pre-treatment functioning, thus predicting actual HRQoL improvement. This effect was even stronger at 1 year after the start of treatment (follow-up). Less consistently than pre-treatment expectancies, the other individual characteristics predicted mental (higher self-efficacy, less worrying, and lower neuroticism) and physical (higher self-efficacy) HRQoL improvement (Table 2).

Sensitivity analyses for shorter-term and longer-term treatment arms are reported in Table 3. Stratification of the duration of antimicrobial treatment (shorter-term versus longer-term treatment) overall showed a similar pattern of associations, with pre-treatment expectancies being the most consistent predictor of HRQoL at end-of-treatment and follow-up in both groups (Table 3). Differences between treatment arms consisted of the lack of predictive value of the demographic characteristics in the shorter-term antimicrobial treatment arm as opposed to the longer-term treatment arms (1–4% vs. 9–18% explained variance) and the larger predictive value of pre-treatment mental HRQoL for end-of-treatment and follow-up mental HRQoL in the shorter-term than longer-term treatment arms (51–52% vs. 28–34% explained variance).

**Post-treatment expectancies of presumed study medication being associated with quality of life course**

At end-of-treatment, more patients presumed to have received antibiotics (n = 148, 64.1%) than placebo (n = 32, 13.9%) during blinded randomized treatment; the remainder indicated not to know (n = 51, 22.1%). A significant difference in presumed study medication was found between the treatment arms, with a larger percentage of patients in the longer-term antibiotics group who (adequately) presumed to have received antibiotics (71.2%) compared to the placebo group (51.8%; p = 0.007), with no difference between the two longer-term groups (doxycycline: 63.1%; clarithromycin: 77.8%; p = 0.12).

When post-treatment expectancies of presumed study medication were included as a post-treatment predictor in the hierarchical regression analyses in an additional block, the explained variance of quality of life at end-of-treatment significantly increased by 2 to 3%, with patients who thought to have received antibiotics showing improvements in all outcome measures at end-of-treatment (14 weeks; PCS: β = 0.14, p = 0.003, 95% CI 1.00:4.75; CIS: β = −0.17, p < 0.001, 95% CI −7.34:−2.22; MCS: β = 0.17, p < 0.001, 95% CI 1.95:6.07). Post-treatment expectancies did not add significantly to physical or mental HRQoL at follow-up (52 weeks; PCS: p = 0.22; CIS: p = 0.24; MCS: p = 0.07). These effects were similar in the shorter-term and longer-term treatment arms for end-of-treatment (14 weeks), whereas post-treatment expectancies were significantly (or with a trend towards significance) associated with physical and mental HRQoL at follow-up in the longer-term treatment arms only (PCS: p = 0.86 vs. 0.08; CIS: p = 0.78 vs. 0.03; MCS: p = 0.70 vs. 0.03 in the shorter-term vs. longer-term treatment arms).

In the previous PLEASE trial [3], it was shown that the antibiotics treatments on top of the short-term ceftriaxone treatment did not lead to a different change in physical or mental HRQoL at end-of-treatment and follow-up than when short-term treatment was followed by placebo. Within the current study, this finding was confirmed when combining the two longer-term antibiotics treatments, showing no significant effect of group on physical or mental HRQoL, when controlling for gender and HRQoL at baseline (PCS: 14 weeks: p = 0.26; 52 weeks: p = 0.77; CIS: 14 weeks: p = 0.93; 52 weeks: p = 0.40; MCS: 14 weeks: p = 0.43; 52 weeks: p = 0.63). Entering whether participants presumed to have received antibiotics instead of actual group allocation showed significant effects on all measures of HRQoL at end-of-treatment (14 weeks; PCS: F(1,230) = 9.78, p = 0.002; CIS: F(1,230) = 12.59, p < 0.001; MCS: F(1,230) = 12.94, p < 0.001). For all HRQoL measures, quality of life was reported to be better in the group of participants who presumed to have received antibiotics (presumed vs. non-presumed antibiotics received: PCS: 37.44 ± 10.23 vs. 34.02 ± 9.72; CIS: 35.39 ± 13.61 vs. 40.33 ± 12.48; MCS: 42.88 ± 11.31 vs. 38.82 ± 10.80). These effects were no longer significant at follow-up (52 weeks; PCS: F(1,169) = 2.22, p = 0.14; CIS: F(1,169) = 1.85, p = 0.18; F(1,169) = 3.70, p = 0.06).

**Discussion**

The current study examined the role of expectancies regarding symptom improvement and other individual characteristics in predicting quality of life course after antimicrobial therapy for
Table 1 Descriptive statistics of the demographic, disease-related, study-related, outcome, and individual characteristics of the patients with complete data at end-of-treatment (14 weeks, \( n = 231 \)) or follow-up (52 weeks, \( n = 170 \))

| Variables                        | End-of-treatment sample \( (n = 231) \) | Follow-up sample \( (n = 170) \) |
|----------------------------------|------------------------------------------|----------------------------------|
| **Demographic factors**          |                                          |                                  |
| Age (mean (SD))                  | 49.88 (11.70)                            | 51.19 (11.55)                    |
| Sex (female) (n (%))             | 106 (45.9)                               | 82 (48.2)                        |
| Steady partner (n (%))           | 201 (87.0)                               | 149 (87.6)                       |
| Education level (n (%))          |                                          |                                  |
| Primary                          | 1 (0.4)                                  | 1 (0.6)                          |
| Secondary                        | 123 (53.2)                               | 84 (49.4)                        |
| Tertiary                         | 107 (46.3)                               | 85 (50.0)                        |
| Smoking (n (%))                  | 56 (24.2)                                | 33 (19.4)                        |
| Paid labor (n (%))               | 143 (61.9)                               | 102 (60.0)                       |
| **Disease-related factors**      |                                          |                                  |
| Duration of symptoms attributed to Lyme disease (years) (median (IQR)) | 2.47 (1.16–6.39) | 2.26 (1.15–6.31) |
| Use of pain medication (n (%))   | 162 (70.1)                               | 115 (67.6)                       |
| **Study-related factors (n (%))**|                                          |                                  |
| Treatment arm                    |                                          |                                  |
| Ceftriaxone followed by doxycycline | 65 (28.1)                               | 47 (27.6)                        |
| Ceftriaxone followed by clarithromycin and hydroxychloroquine | 81 (35.1) | 59 (34.7) |
| Ceftriaxone followed by placebo  | 85 (36.8)                                | 64 (37.6)                        |
| **Health-related quality of life (mean (SD))** |                                          |                                  |
| **Physical HRQoL**               |                                          |                                  |
| Physical component summary score (RAND SF-36, T-score) |                              |                                  |
| Pre-treatment                    | 31.81 (7.47)                             | 31.91 (7.50)                     |
| End-of-treatment (14 weeks)      | 36.21 (10.16)                            | 36.14 (10.16)                    |
| Follow-up (52 weeks)             | 37.60 (11.38)                            |                                  |
| Fatigue severity (CIS)           |                                          |                                  |
| Pre-treatment                    | 43.79 (10.09)                            | 44.09 (9.71)                     |
| End-of-treatment (14 weeks)      | 37.17 (13.40)                            | 37.07 (13.80)                    |
| Follow-up (52 weeks)             | 35.72 (14.66)                            |                                  |
| **Mental HRQoL**                 |                                          |                                  |
| Mental component summary score (RAND SF-36, T-score) |                      |                                  |
| Pre-treatment                    | 37.75 (9.57)                             | 37.38 (9.36)                     |
| End-of-treatment (14 weeks)      | 41.42 (11.28)                            | 41.51 (11.34)                    |
| Follow-up (52 weeks)             | 42.08 (11.60)                            |                                  |
| **Individual characteristics (mean (SD))** |                                          |                                  |
| Expectancies regarding symptom improvement | 16.12 (4.46) | 16.25 (4.43) |
| Self-efficacy (LSE)              | 17.23 (5.36)                             | 17.37 (4.99)                     |
| Illness cognitions (ICQ)         |                                          |                                  |
| Helplessness regarding disease   | 13.50 (4.24)                             | 13.52 (4.34)                     |
| Disease acceptance               | 13.87 (3.89)                             | 14.02 (3.90)                     |
| Perceived disease benefits       | 11.64 (4.13)                             | 11.69 (4.21)                     |
| Worrying (PSWQ)                  | 41.91 (12.28)                            | 42.16 (12.31)                    |
| Personality (EPQ)                |                                          |                                  |
| Neuroticism                      | 7.94 (5.16)                              | 7.87 (5.24)                      |
| Extraversion                     | 11.49 (4.63)                             | 10.79 (4.50)                     |

*CIS*, Checklist Individual Strength – Fatigue severity subscale; *EPQ*, Eysenck Personality Questionnaire; *ICQ*, Illness Cognition Questionnaire; *IQR*, interquartile range; *LSE*, Lyme Self-Efficacy; *PSWQ*, Penn-State Worry Questionnaire; *RAND SF-36*, RAND-36 Health Status Inventory; *SD*, standard deviation.
regarding symptom course or treatment outcome, has been minimization of nocebo effects [23, 27, 38, 39]. By contrast, where the main outcomes of our PLEASE-trial showed that expectancy characteristics, such as the tendency to have faith in one’s abilities to deal with adversities (i.e., self-efficacy), to worry about potential negative future events (i.e., worrying), and to experience negative emotional states and to view the world as threatening (i.e., neuroticism). The current study examined the relative predictive contribution of situation-specific expectancies next to other potentially relevant individual characteristics, of which only these more generalized outcome expectancies were studied mostly within the area of placebo research. In this research, it has for instance been shown that induction of positive expectancies by means of learning procedures such as conditioning and verbal suggestions leads to decreased experience of physical symptoms such as pain and itch [40, 41]. Placebo effects have traditionally mainly been examined in the context of placebo-controlled randomized trials to discriminate the “real” treatment effect from other “random” effects [42]. Currently, however, evidence has been accumulating that indicates the large clinical potential of implementing the placebo effect into the clinic to optimize patient care [23]. Situation-specific or treatment-specific expectancies have not often been examined as predictors of treatment outcome or symptom course in clinical trials up to now. This is in contrast to more generalized outcome expectancy characteristics, such as the tendency to have faith in one’s abilities to deal with adversities (i.e., self-efficacy), to worry about potential negative future events (i.e., worrying), and to experience negative emotional states and to view the world as threatening (i.e., neuroticism). The current study examined the relative predictive contribution of situation-specific expectancies next to other potentially relevant individual characteristics, of which only these more generalized outcome expectancies were

Table 2 Percentage of explained variance and standardized regression coefficients (95% confidence intervals) of predictors of physical and mental health–related quality of life at end-of-treatment (14 weeks, n = 231) and follow-up (52 weeks, n = 170) in the total group (shorter- and longer-term treatment arms combined)

| Predictor | Physical HRQoL | Mental HRQoL |
|-----------|----------------|-------------|
|           | Physical component summary score (RAND-36 PCS) | Fatigue severity (CIS) | Mental component summary score (RAND-36 MCS) |
| Demographic characteristics | | | |
| ΔR² | .12* | .08** | .05** |
| Paid labor | .17* (.16; 5.49) | .13* (.34; 5.87) | .12* (.59; 4.91) |
| Smoking | –.04 (–.30; 1.24) | –.08 (–5.52; 1.15) | –.09# (–.43; .15) |
| Pre-treatment HRQoL | ΔR² | .38† | .40† |
| Pre-treatment PCS/CIS/MCS | .52† (.55; .86) | .36† (.32; .76) | .38† (.30; .60) |
| Individual characteristics | ΔR² | .05† | .09† |
| Expectancies symptom improvement | .14** (.09; .54) | .23† (.27; .92) | .38† (.30; .65) |
| Self-efficacy (LSE) | .09 (–.04; .38) | .16* (.05; .69) | .13* (.06; .50) |
| Worrying (PSWQ) | –.08 (–.17; .04) | .04 (–.12; .19) | –.17* (–.28; –.03) |
| Neuroticism (EPQ) | –.10 (–.45; .05) | –.17# (–.76; .004) | –.17* (–.65; –.01) |
| Total R² | .54† | .45† | .54† |

#p < .10, *p < .05, **p < .01, †p < .001; percentage of explained variance (Δ and total R²), and standardized regression coefficients (β, 95% CI) were assessed by means of hierarchical regression analyses; predictors were included when at least one significant association was found in prior regression analyses including all predictors showing any significant zero-order association with any of the outcome measures at end-of-treatment (14 weeks) or follow-up (52 weeks)

Abbreviations: CIS, Checklist Individual Strength - Fatigue severity subscale; EPQ, Eysenck Personality Questionnaire; HRQoL, health-related quality of life; ICQ, Illness Cognition Questionnaire; LSE, Lyme Self-Efficacy scale; RAND-36, RAND SF-36 Health Status Inventory - MCS, mental component summary score; PSWQ, Penn-State Worry Questionnaire; RAND-36 PCS, RAND SF-36 Health Status Inventory – physical component summary score.

Persistent symptoms attributed to Lyme disease. In addition to pre-treatment functioning, pre-treatment expectancies regarding symptom improvement and post-treatment expectancies on having received antibiotics were found to be consistent predictors of larger improvements in physical and mental HRQoL. Other individual characteristics, related to more generalized outcome expectancies, showed less consistent predictive associations. Thus, where the main outcomes of our PLEASE-trial showed that the two specific standardized longer-term antimicrobial therapies did not have significant added benefits over shorter-term treatment for the quality of life outcomes at group level [3], the current study showed that expectancies regarding symptom improvement and received study medication are associated with symptom course after both shorter-term and longer-term antimicrobial treatment. These findings suggest that expectancies are relevant to consider in treatment studies and may be useful in clinical settings to improve symptom course and treatment outcome, which is in line with the current upsurge of research into the clinical potential of optimization of placebo effects and minimization of nocebo effects [23, 27, 38, 39]. The role of positive or negative expectancies, for example regarding symptom course or treatment outcome, has been studied in various clinical settings, and the results suggest that these expectancies can have a significant impact on treatment outcomes. However, the specific factors that influence these expectancies, such as individual characteristics or previous treatment experiences, remain largely unknown.
Table 3  Percentage of explained variance and standardized regression coefficients (95% confidence intervals) of predictors of physical and mental health–related quality of life at end-of-treatment (14 weeks, \( n = 231 \)) and follow-up (52 weeks, \( n = 170 \)) in the shorter-term (ST) versus longer-term (LT) treatment arms

| Predictor variable | Rx | Physical HRQoL | Fatigue severity (CIS) | Mental HRQoL |
|--------------------|----|----------------|-----------------------|--------------|
|                    |    | Physical component summary score (RAND-36 PCS) | Week 14 | Week 52 | Week 14 | Week 52 | Week 14 | Week 52 |
| Demographic charac- |    |                |                       |              |
| teristics          |    |                |                       |              |
| Paid labor         |    |                |                       |              |
| ST                 | .09 (−1.33; 5.32) | .16 (−1.47; 9.50) | −.08 (−7.08; 2.45) | .01 (0.99; 1.01) |
| LT                 | 2.11 (2.08; 7.22) | .11 (−1.04; 5.70) | −.17 (−8.01; −1.12) | .14 (4.08; 8.02) |
| Smoking            |    |                |                       |              |
| ST                 | −.04 (−4.52; 2.82) | −.04 (−7.51; 5.27) | −.05 (−6.67; 3.80) | .03 (6.55; 8.61) |
| LT                 | −.04 (−3.82; 1.82) | −.12 (−7.28; 76) | −.04 (−2.52; 5.08) | −.14 (−8.20; −0.02) |
| Pre-treatment HRQoL|    |                |                       |              |
| Pre-treatment PCS/CIS/ |    |                |                       |              |
| MCS                | ST   | .58 (−.49; .99) | .28 (−.01; .86) |                             |                             |
| LT                 | .48 (−.47; .89) | .39 (33, 84) | .46 (−.45; .82) | .49 (50, 97) |
| Individual character- |    |                |                       |              |
| stistics           |    |                |                       |              |
| Expectancies symptom improvement |    | | | |
| ST                 | .12 (−.10; .58) | .18 (−12; 1.01) | −.18 (−.97; 0.01) | −.18 (−.12; 0.09) |
| LT                 | .15 (−.06; .66) | .30 (−38; 1.24) | −.20 (−1.05; −.25) | −.28 (−1.43; −.46) |
| Self-efficacy (LSE) |    |                |                       |              |
| ST                 | .12 (−.13; .54) | .19 (−17; 1.05) | −.07 (−.66; .32) | −.07 (−.91; .52) |
| LT                 | .06 (−.16; .42) | .13 (−.09; .88) | −.15 (−.78; .03) | −.05 (−.59; .29) |
| Worrying (PSWQ)    |    |                |                       |              |
| ST                 | −.06 (−.25; .11) | −.08 (−.40; .23) | .05 (−.21; .33) | .18 (−.15; .60) |
| LT                 | −.08 (−.20; .07) | .17 (−.06; .36) | .05 (−.13; .24) | .10 (−.10; .33) |
| Neuroticism (EPQ)  |    |                |                       |              |
| ST                 | −.06 (−.58; .25) | −.16 (−1.09; .33) | .18 (−.15; .17) | .11 (−.52; 1.17) |
| LT                 | −.11 (−.54; .12) | −.25 (−.39; −.03) | .09 (−.21; .67) | .03 (−.44; .63) |
| Total \( R^2 \)    |    |                |                       |              |
| ST                 | .59 | .41 | .49 | .47 |
| LT                 | .53 | .51 | .53 | .55 |

*\( p < .10 \), †\( p < .05 \), ‡\( p < .01 \), ††\( p < .001 \); percentage of explained variance (\( \Delta \) and total \( R^2 \)) and standardized regression coefficients (\( \beta \), 95% CI) were assessed by means of hierarchical regression analyses; predictors were included in case at least one significant association was found in prior regression analyses including all predictors showing any significant zero-order association with any of the outcome measures at end-of-treatment (14 weeks) or follow-up (52 weeks).

Abbreviations: CIS, Checklist Individual Strength - Fatigue severity subscale; EPQ, Eysenck Personality Questionnaire; HRQoL, health-related quality of life; ICQ, Illness Cognition Questionnaire; LSE, Lyme Self-Efficacy scale; RAND-36, RAND SF-36 Health Status Inventory - MCS, mental component summary score; PSWQ, Penn-State Worry Questionnaire; RAND-36 PCS, RAND SF-36 Health Status Inventory – physical component summary score; Rx, shorter-term (ST) or longer-term (LT) antimicrobial therapy.
found to be relevant. The results clearly showed that situation-specific pre-treatment and post-treatment expectancies were the most consistent predictors of quality of life course at end-of-treatment and, for pre-treatment expectancies, even more strongly at follow-up. Of the more generalized outcome expectancy characteristics, less consistent associations were found for self-efficacy, worrying, and neuroticism. Although in line with previous studies in other chronic conditions [9, 11–13], it indicates less consistent evidence regarding the potential predictive value of more generalized as opposed to situation-specific outcome expectancies. This agrees with the findings of our previous study on an immune-related training program in healthy men, in which situation-specific outcome expectancies were found to be associated to clinical symptom report after endotoxin administration [18]. The findings of the current study thus suggest the added value of both pre-treatment and post-treatment expectancies in explaining individual differences in treatment success regarding symptom course or treatment outcome in patients with persistent symptoms attributed to Lyme disease and possibly also other chronic conditions.

Patients with persistent symptoms attributed to Lyme disease report a high symptom burden and disability, and low quality of life [1, 3]. As specific standardized protocols of prolonged antimicrobial therapy have mostly not lead to improved treatment outcomes at group level [3–5], it is relevant to find factors associated with outcomes that treatment could be tailored to or other ways to improve symptom course and treatment outcome for this patient group. Patients with persistent symptoms for whom there is no gold standard treatment, such as the patients in our study, will have a high chance of having been confronted with negative treatment experiences. These negative experiences will automatically and unintentionally lead to negative outcome expectancies regarding new treatments. To prevent further disappointment, health care professionals tend to be hesitant to induce any positive expectancies in their patients [43]. However, as the current study illustrates, pre-treatment expectancies of symptom improvement are relevant predictors of quality of life in both the shorter-term and longer-term treatment arms. This underscores the relevance of examining different ways to optimize expectancies in clinical practice to potentially improve treatment outcomes in this high-burdened patient group, for example by means of enhanced doctor-patient communication and open-label placebo treatments [44] in which patients are informed about receiving a placebo and its working mechanisms. That the most consistent and long-lasting effects were found for the patients receiving longer-term antimicrobial therapy, specifically regarding post-treatment expectancies, may reflect that patients did notice somehow whether or not they received longer-term antibiotics, which probably has impacted their expectancies. Alternatively, it could be explained by the lower power in the shorter-term group, as the two longer-term treatment arms were combined in the analyses.

The current study extended on the main findings of the PLEASE trial by showing that the improvements in quality of life from pre-treatment up to 1 year after start of treatment, which could on group level not be attributed to added benefits of the specific longer-term antimicrobial treatment regimens provided on top of 2-week ceftriaxone treatment [3], are associated with pre-treatment expectancies regarding symptom improvement. Also, the current findings suggest treatment outcome to be more strongly associated with presumed antibiotic use than with actual antibiotic use. The fact that the question on presumed medication use was merely asked immediately after treatment allows for a bidirectional interpretation of the findings (i.e., treatment improvements impacting on the belief that one has received antibiotics versus believing one has received antibiotics impacting on treatment outcomes). However, presumed medication use remained a significant, although less strong, predictor of outcomes up to 1 year after start of treatment (38 weeks after presumed medication assessment) within the longer-term treatment arms. Thus, although the two types of longer-term antimicrobial therapy have not shown at group level to be more effective than the 2-week antimicrobial treatment that all patients in this study received, our patients may ascribe positive expectancies towards this treatment, which are related to a more positive outcome. This suggests the relevance of optimizing patient expectancies before the start of new treatment, of course within ethical boundaries [27].

Strengths of the current study include the large sample size and rigorous RCT study design. Also, the inclusion of pre-treatment functioning in the regression analysis provides a more stringent test of the added value of individual characteristics in actually predicting the change in HRQoL from baseline to end-of-treatment or follow-up. Limitations include the self-report nature of all predictor and outcome measures, allowing potential response bias effects. Also, the difference in patient numbers at end-of-treatment and follow-up prevents direct comparability of findings, and the lower power in the shorter-term compared to the combined longer-term treatment arms complicates the interpretation of differences in predictions between groups. Finally, the assessment of post-treatment expectancies brings inherent interpretability problems due to its assessment being intertwined with outcome assessment.

To conclude, the present study shows how patients’ pre-treatment and post-treatment expectancies regarding improvement of persistent symptoms attributed to Lyme disease can, next to pre-treatment functioning, explain a more beneficial symptom course. It would be relevant to examine in future research how expectancies could be optimized in patients with persistent symptoms attributed to Lyme disease, for instance by enhanced doctor-patient communication, in order to potentially improve symptom course and treatment effectiveness. These results underscore recommendations to (1) ascertain that patient pre-treatment expectancies are realistic and can be met, and (2) inform patients and clinicians about the role of expectancies and taking these into account in treatments and research trials.
## Appendix

### Table 4  Descriptive statistics and comparisons of the demographic, disease-related, study-related, outcome, and individual characteristics of the completer sample at end-of-treatment (14 weeks; \(n = 231\)) versus non-completers (\(n = 49\))

| Variables                                      | Completer end-of-treatment sample (\(n = 231\)) | Non-completer end-of-treatment sample (\(n = 49\)) | \(p\)-value |
|------------------------------------------------|-----------------------------------------------|---------------------------------------------------|--------------|
| **Demographic factors**                        |                                               |                                                   |              |
| Age (mean (SD))                                 | 49.88 (11.70)                                 | 46.42 (12.44)                                    | 0.06         |
| Sex (female) (\(n\) (%))                      | 106 (45.9)                                    | 23 (46.9)                                        | 0.89         |
| Steady partner (\(n\) (%))                    | 201 (87.0)                                    | 38 (80.9)                                        | 0.27         |
| Education level (\(n\) (%))                   |                                               |                                                   | 0.31         |
| Primary                                        | 1 (0.4)                                       | 0 (0.0)                                          |              |
| Secondary                                      | 123 (53.2)                                    | 30 (65.2)                                        |              |
| Tertiary                                       | 107 (46.3)                                    | 16 (34.8)                                        |              |
| Smoking (\(n\) (%))                            | 56 (24.2)                                     | 8 (16.7)                                         | 0.26         |
| Paid labor (\(n\) (%))                         | 143 (61.9)                                    | 28 (59.6)                                        | 0.77         |
| **Disease-related factors**                    |                                               |                                                   |              |
| Duration of symptoms attributed to Lyme disease (years) (median (IQR)) | 2.47 (1.16–6.39) | 2.55 (1.27–4.27) | 0.24 |
| Use of pain medication (\(n\) (%))             | 162 (70.1)                                    | 28 (59.6)                                        | 0.16         |
| **Study-related factors (\(n\) (%))**          |                                               |                                                   | 0.12         |
| Treatment arm                                  |                                               |                                                   |              |
| Ceftriaxone followed by doxycycline            | 65 (28.1)                                     | 21 (42.9)                                        |              |
| Ceftriaxone followed by clarithromycin and hydroxychloroquine | 81 (35.1)                                    | 15 (30.6)                                        |              |
| Ceftriaxone followed by placebo                | 85 (36.8)                                     | 13 (26.5)                                        |              |
| **Health-related quality of life (mean (SD))** |                                               |                                                   |              |
| Physical HRQoL                                  |                                               |                                                   |              |
| Physical component summary score (RAND SF-36, T-score) | 31.81 (7.47)                                 | 30.90 (7.13)                                     | 0.44         |
| Pre-treatment                                   | 31.81 (7.47)                                  | 30.90 (7.13)                                     | 0.44         |
| End-of-treatment (14 weeks)                     | 36.21 (10.16)                                 | 38.50 (11.19; \(n = 30\))                       | 0.25         |
| Fatigue severity (CIS)                          | 43.79 (10.09)                                 | 45.62 (9.48)                                     | 0.25         |
| Pre-treatment                                   | 43.79 (10.09)                                 | 45.62 (9.48)                                     | 0.25         |
| End-of-treatment (14 weeks)                     | 37.17 (13.40)                                 | 34.92 (15.09; \(n = 31\))                       | 0.39         |
| Mental HRQoL                                    |                                               |                                                   |              |
| Mental component summary score (RAND SF-36, T-score) | 37.75 (9.57)                                | 35.49 (10.44)                                    | 0.15         |
| Pre-treatment                                   | 37.75 (9.57)                                  | 35.49 (10.44)                                    | 0.15         |
| End-of-treatment (14 weeks)                     | 41.42 (11.28)                                 | 45.81 (13.16; \(n = 26\))                       | 0.11         |
| **Individual characteristics (mean (SD))**     |                                               |                                                   |              |
| Expectancies regarding symptom improvement      | 16.12 (4.46)                                  | 17.49 (4.02)                                     | 0.07         |
| Self-efficacy (LSE)                             | 17.23 (5.36)                                  | 16.21 (5.13)                                     | 0.23         |
| Illness cognitions (ICQ)                        |                                               |                                                   |              |
| Helplessness regarding disease                  | 13.50 (4.24)                                  | 13.94 (4.52)                                     | 0.52         |
| Disease acceptance                              | 13.87 (3.89)                                  | 12.53 (4.11)                                     | 0.03         |
| Perceived disease benefits                      | 11.64 (4.13)                                  | 10.93 (3.93)                                     | 0.28         |
| Worrying (PSWQ)                                 | 41.91 (12.28)                                 | 43.39 (13.48)                                    | 0.46         |
| Personality (EPQ)                               |                                               |                                                   |              |
| Neuroticism                                     | 7.94 (5.16)                                   | 9.51 (5.36)                                      | 0.06         |
| Extraversion                                    | 11.49 (4.63)                                  | 11.89 (5.22)                                     | 0.62         |
| Presumed medication use (\(n\) (%))            |                                               |                                                   | 0.52         |
| Antibiotics                                     | 148 (64.1)                                    | 26 (72.2)                                        |              |
| Placebo                                         | 32 (13.9)                                     | 5 (13.9)                                         |              |
| Not known                                       | 51 (22.1)                                     | 5 (13.9)                                         |              |

CIS, Checklist Individual Strength – Fatigue Severity Subscale; EPQ, Eysenck Personality Questionnaire; ICQ, Illness Cognition Questionnaire; IQR, interquartile range; LSE, Lyme Self-Efficacy; PSWQ, Penn-State Worry Questionnaire; RAND SF-36, RAND-36 Health Status Inventory; SD, standard deviation
Table 5  Descriptive statistics and comparisons of the demographic, disease-related, study-related, outcome, and individual characteristics of the completer sample at follow-up (52 weeks; \( n = 170 \)) versus drop-outs between end-of-treatment (14 weeks) and follow-up (52 weeks; \( n = 66 \))

| Variables                                      | Completer follow-up sample \((n = 170)\) | Drop-outs between end-of-treatment and follow-up \((n = 66)\) | \( p \)-value |
|-----------------------------------------------|------------------------------------------|-------------------------------------------------------------|--------------|
| Demographic factors                           |                                          |                                                             |              |
| Age (mean (SD))                               | 51.19 (11.55)                            | 45.88 (11.85)                                               | 0.002        |
| Sex (female) (\( n \) (%))                   | 82 (48.2)                                | 26 (39.4)                                                   | 0.22         |
| Steady partner (\( n \) (%))                  | 149 (87.6)                               | 57 (86.4)                                                   | 0.79         |
| Education level (\( n \) (%))                 |                                          |                                                             | 0.13         |
| Primary                                       | 1 (0.6)                                  | 0 (0.0)                                                     |              |
| Secondary                                     | 84 (49.4)                                | 42 (63.6)                                                   |              |
| Tertiary                                      | 85 (50.0)                                | 24 (36.4)                                                   |              |
| Smoking (\( n \) (%))                         | 33 (19.4)                                | 23 (34.8)                                                   | 0.01         |
| Paid labor (\( n \) (%))                      | 102 (60.0)                               | 44 (66.7)                                                   | 0.34         |
| Disease-related factors                       |                                          |                                                             |              |
| Duration of symptoms attributed to Lyme disease (years) (median (IQR)) | 2.26 (1.15–6.31) | 2.75 (1.20–6.42) | 0.56 |
| Use of pain medication (\( n \) (%))          | 115 (67.6)                               | 50 (75.8)                                                   | 0.22         |
| Study-related factors (\( n \) (%))           |                                          |                                                             |              |
| Treatment arm                                 |                                          |                                                             | 0.82         |
| Ceftriaxone followed by doxycycline           | 47 (27.6)                                | 20 (30.3)                                                   |              |
| Ceftriaxone followed by clarithromycin and hydroxychloroquine | 59 (34.7) | 24 (36.4) | |
| Ceftriaxone followed by placebo               | 64 (37.6)                                | 22 (33.3)                                                   |              |
| Health-related quality of life (mean (SD))   |                                          |                                                             |              |
| Physical HRQoL                                 |                                          |                                                             |              |
| Physical component summary score (RAND SF-36, T-score) | 31.91 (7.50) | 31.48 (7.32) | 0.70 |
| Fatigue severity (CIS)                        |                                          |                                                             |              |
| Pre-treatment                                 | 44.09 (9.71)                             | 43.16 (10.85)                                               | 0.52         |
| End-of-treatment (14 weeks)                   | 37.07 (13.80)                            | 37.24 (12.29)                                               | 0.93         |
| Mental HRQoL                                  |                                          |                                                             |              |
| Mental component summary score (RAND SF-36, T-score) | 37.38 (9.36) | 38.47 (9.95) | 0.43 |
| End-of-treatment (14 weeks)                   | 41.51 (11.34)                            | 41.44 (11.31)                                               | 0.97         |
| Individual characteristics (mean (SD))        |                                          |                                                             |              |
| Expectancies regarding symptom improvement    | 16.25 (4.43)                             | 15.83 (4.44)                                                | 0.51         |
| Self-efficacy (LSE)                           | 17.37 (4.99)                             | 16.83 (6.20)                                                | 0.53         |
| Illness cognitions (ICQ)                      |                                          |                                                             |              |
| Helplessness regarding disease                | 13.52 (4.34)                             | 13.48 (4.01)                                                | 0.96         |
| Disease acceptance                            | 14.02 (3.90)                             | 13.43 (3.83)                                                | 0.29         |
| Perceived disease benefits                    | 11.69 (4.21)                             | 11.44 (3.94)                                                | 0.67         |
| Worrying (PSWQ)                               | 42.16 (12.31)                            | 41.60 (12.40)                                               | 0.76         |
| Personality (EPQ)                             |                                          |                                                             |              |
| Neuroticism                                   | 7.87 (5.24)                              | 8.17 (4.96)                                                 | 0.69         |
| Extraversion                                  | 10.79 (4.50)                             | 13.51 (4.43)                                                | <0.001       |
| Presumed medication use (\( n \) (%))         |                                          |                                                             | 0.87         |
| Antibiotics                                   | 111 (65.3)                               | 41 (62.1)                                                   |              |
| Placebo                                       | 23 (13.5)                                | 9 (13.6)                                                    |              |
| Not known                                     | 36 (21.2)                                | 16 (24.2)                                                   |              |

CIS, Checklist Individual Strength – Fatigue severity subscale; EPQ, Eysenck Personality Questionnaire; ICQ, Illness Cognition Questionnaire; IQR, interquartile range; LSE, Lyme Self-Efficacy; PSWQ, Penn-State Worry Questionnaire; RAND SF-36, RAND-36 Health Status Inventory; SD, standard deviation
Author contribution All authors contributed to the study conception and design. Material preparation, data collection, and analysis were performed by Henriët van Middendorp, Anneleen Berende, Andrea WM Evers, and Bart Jan Kullberg. The first draft of the manuscript was written by Henriët van Middendorp, and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

Funding This study was supported by a grant (171002304) from the Netherlands Organization for Health Research and Development ZonMw. The funders had no role in study design, data collection or analysis, decision to publish, or writing this manuscript.

Data availability The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

Declarations

Ethics approval The study was ethically approved by the Medical Ethics Review Committee CMO Region Arnhem-Nijmegen (registration number 2009/187, NL27344.091.09). This study was performed in line with the principles of the Declaration of Helsinki.

Consent to participate All participants provided written informed consent to be included in the study and their aggregated data to be used for scientific publications.

Disclosures None.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Van den Wijngaard CC, Hofhuis A, Harms MG, Haagsma JA, Wong A, De Wit GA, Havelaar AH, Lugner AK, Suijkerbuijk AWM, Van Pelt W (2015) The burden of Lyme borreliosis expressed in disability-adjusted life years. Eur J Public Health 25:1071–1078
2. Cairns V, Godwin J (2005) Post-Lyme borreliosis syndrome: a meta-analysis of reported symptoms. Int J Epidemiol 34:1340–1345
3. Berende A, Ter Hofstede HJM, Vos FJ, Van Middendorp H, Vogelaar ML, Tromp M, Van den Hoogen FH, Donders ART, Evers AWM, Kullberg BJ (2016) Randomized trial of longer-term therapy for symptoms attributed to Lyme disease. N Engl J Med 374:1209–1220
4. Klemperer MS, Hu LT, Evans J, Schmid CH, Johnson GM, Trevino RP, Norton D, Levy L, Wall D, McCall J, Kosinski M, Weinstein A (2001) Two controlled trials of antibiotic treatment in patients with persistent symptoms and a history of Lyme disease. N Engl J Med 345:85–92
5. Krupp LB, Hyman LG, Grimson R, Coyle PK, Melville P, Ahlm S, Dattwyler R, Chandler B (2003) Study and treatment of post Lyme disease (STOP-LD) - a randomized double masked clinical trial. Neurology 60:1923–1930
6. Cameron D (2008) Severity of Lyme disease with persistent symptoms. Insights from a double-blind placebo-controlled clinical trial. Minerva Med 99:489–496
7. Aucott JN, Crowder LA, Korte KB (2013) Development of a foundation for a case definition of post-treatment Lyme disease syndrome. Int J Infect Dis 17:E443–E449
8. Wormser GP, Weitzner E, McKenna D, Nadelman RB, Savaarda C, Nowakowski J (2015) Long-term assessment of fatigue in patients with culture-confirmed Lyme disease. Am J Med 128:181–184
9. Chandra AM, Keilp JG, Fallon BA (2013) Correlates of perceived health-related quality of life in post-treatment Lyme encephalopathy. Psychosomatics 54:552–559
10. Fleming RV, Marques AR, Klemperer MS, Schmid CH, Dally LG, Martin DS, Philipp MT (2004) Pre-treatment and post-treatment assessment of the C-6 test in patients with persistent symptoms and a history of Lyme borreliosis. Eur J Clin Microbiol Infect Dis 23:615–618
11. Van Middendorp H, Evers AWM (2016) The role of psychological factors in inflammatory rheumatic diseases: from burden to tailored treatment. Best Pract Res Clin Rheumatol 30:932–945
12. Samwel HJA, Kraaimaat FW, Cruc BJF, Van Dongen RD, Evers AWM (2009) Multidisciplinary allocation of chronic pain treatment: effects and cognitive–behavioural predictors of outcome. Br J Health Psychol 14:405–421
13. Evers AWM, Verhoeven EWM, Van Middendorp H, Sweep FCGJ, Kraaimaat FW, Donders ART, Eijsbouts AE, Van Laarhoven AIM, De Brouwer SIM, Wirken L, Radstake TRDJ, Van Riel PLCM (2014) Does stress affect the joints? Daily stressors, stress vulnerability, immune and HPA axis activity, and short-term disease and symptom fluctuations in rheumatoid arthritis. Ann Rheum Dis 73:1683–1688
14. Benedetti F, Carlino E, Piedimonte A (2016) Increasing uncertainty in CNS clinical trials: the role of placebo, nocebo, and Hawthorne effects. Lancet Neurol 15:736–747
15. Cormier S, Lavigne GL, Choiniere M, Rainville P (2016) Expectations predict chronic pain treatment outcomes. Pain 157:329–338
16. Goossens ME, Vlaeyen JW, Hidding A, Kole-Snijders A, Evers SM (2005) Treatment expectancy affects the outcome of cognitive-behavioural interventions in chronic pain. Clin J Pain 21:18–26
17. Khan JS, Devereaux PJ, LeManach Y, Busse JW (2016) Patient coping and expectations about recovery predict the development of chronic post-surgical pain after traumatic tibial fracture repair. Br J Anaesth 117:365–370
18. Van Middendorp H, Kox M, Pickkers P, Evers AWM (2016) The role of outcome expectancies for a training program consisting of meditation, breathing exercises, and cold exposure on the response to endotoxin administration: a proof-of-principle study. Clin Rheumatol 35:1081–1085
19. Pan YQ, Heisig SR, Von Blanckenburg P, Albert US, Hadji P, Rief W, Nestoriuc Y (2018) Facilitating adherence to endocrine therapy in breast cancer: stability and predictive power of treatment expectations in a 2-year prospective study. Breast Cancer Res Treat 168:667–677
20. Auer CJ, Glombiewski JA, Doering BK, Winkler A, Laferton JAC, Broadhent E, Rief W (2016) Patients’ expectations predict surgery outcomes: a meta-analysis. Int J Behav Med 23:49–62
21. Hartkamp A, Geenen R, Godeaert GLR, Bootma H, Kruize AA, Bijlsma JWJ, Derksen RHHM (2008) Effect of dehydroepiandrosterone administration on fatigue, well-being, and functioning in women with primary Sjogren syndrome: a randomised controlled trial. Ann Rheum Dis 67:91–97
22. Kam-Hansen S, Jakubowski M, Kelley JM, Kirsch I, Hoaglin DC, Kaptchuk TJ, Burstein R (2014) Altered placebo and drug labeling
changes the outcome of episodic migraine attacks. Sci Transl Med 6(218):7
23. Peerdeman KJ, Van Laarhoven AM, Keij SM, Vase L, Rovers MM, Peters ML, Evers AWM (2016) Relieving patients’ pain with expectation interventions: a meta-analysis. Pain 157:1179–1191
24. Kube T, Glombiewski JA, Rief W (2018) Using different expectation mechanisms to optimize treatment of patients with medical conditions: a systematic review. Psychosom Med 80:535–543
25. Auer CJ, Laferton JAC, Shedden-Mora MC, Salzmann S, Moosdorf R, Rief W (2017) Optimizing preoperative expectations leads to a shorter length of hospital stay in CABG patients: further results of the randomized controlled PSYHEART trial. J Psychosom Res 97:82–89
26. Rief W, Shedden-Mora MC, Laferton JAC, Auer C, Petrie KJ, Salzmann S, Schedlowski M, Moosdorf R (2017) Preoperative optimization of patient expectations improves long-term outcome in heart surgery patients: results of the randomized controlled PSYHEART trial. BMC Med 15:13
27. Evers AWM, Colloca L, Blease C, Annoni M, Atlas LY, Benedetti F, Bingle U, Buchel C, Carvalho C, Colagiarri B, Crum AJ, Enck P, Gaab J, Geers AL, Howick J, Jensen KB, Kirsch I, Meissner K, Napadow V, Peerdeman KJ, Raz A, Rief W, Vase L, Wager TD, Wampold BE, Weimer K, Wiech K, Kaptchuk TJ, Klingler R, Kelley JM (2018) Implications of placebo and nocebo effects for clinical practice: expert consensus. Psychoter Psychosom 87:204–210
28. Kong J, Wang ZJ, Leiser J, Minicucci D, Edwards R, Kirsch I, Wasan AD, Lang C, Gerber J, Yu SY, Napadow V, Kaptchuk TJ, Gollub RL (2018) Enhancing treatment of osteoarthritis knee pain by boosting expectancy: a functional neuroimaging study. NeuroImage-Clin 18:325–334
29. Berende A, Ter Hofstede HJM, Donders ART, Van Middendorp H, Kessels RPC, Adang EMM, Vos FJ, Evers AWM, Kullberg BJ (2014) Persistent Lyme Empiric Antibiotic Study Europe (PLEASE) - design of a randomized controlled trial of prolonged antibiotic treatment in patients with persistent symptoms attributed to Lyme borreliosis. BMC Infect Dis 14:543
30. Hays RD (1998) RAND-36 health status inventory. San Antonio: The Psychological Corporation
31. Vercoulen JHMM, Hommes OR, Swanink MA, Jongen JH, Fennis JFM, Galama JMD, Van Der Meer JWM, Bleijenberg G (1996) The measurement of fatigue in patients with multiple sclerosis - a multidimensional comparison with patients with chronic fatigue syndrome and healthy subjects. Arch Neurol 53:642–649
32. Den Boer JJ, Oostendorp RAB, Beems T, Munneke M, Evers AWM (2006) Continued disability and pain after lumbar disc surgery: the role of cognitive-behavioral factors. Pain 123:45–52
33. Lorig K, Chastain RL, Eng E, Shoor S, Holman HR (1989) Development and evaluation of a scale to measure perceived self-efficacy in people with arthritis. Arthritis Rheum 32:37–44
34. Evers AW, Kraimaat FW, van Lankveld W, Jongen PJ, Jacobs JW, Bijlsma JW (2001) Beyond unfavorable thinking: the Illness Cognition Questionnaire for chronic diseases. J Consult Clin Psychol 69:1026–1036
35. Van Rijsoort S, Emmelkamp P, Vervaes G (1999) The Penn State Worry Questionnaire and the Worry Domains Questionnaire: structure, reliability and validity. Clin Psychol Psychother 6:297–307
36. Eysenck HJ, Eysenck SBG (1975) The Eysenck Personality Questionnaire. London: Hodder & Stoughton
37. Tabachnick BG, Fidell LS (2001) Using multivariate statistics. Boston: Allyn and Bacon
38. Colloca L (2017) Nocebo effects can make you feel pain. Science 358(6359):44
39. Benedetti F (2014) Placebo effects: from the neurobiological paradigm to translational implications. Neuron 84:623–637
40. Peerdeman KJ, Van Laarhoven AM, Peters ML, Evers AWM (2016) An integrative review of the influence of expectancies on pain. Front Psychol 7:1270
41. Van Laarhoven AM, Vogelaar ML, Wilder-Smith OH, Van Riel P, Van de Kerkhof PCM, Kraimaat FW, Evers AWM (2011) Induction of nocebo and placebo effects on itch and pain by verbal suggestions. Pain 152:1486–1494
42. Enck P, Bingle U, Schedlowski M, Rief W (2013) The placebo response in medicine: minimize, maximize or personalize? Nat Rev Drug Discov 12:191–204
43. Manaï M, Van Middendorp H, Veldhuijzen DS, Huizinga TWJ, Evers AWM (2019) How to prevent, minimize, or extinguish nocebo effects in pain: a narrative review on mechanisms, predictors, and interventions. Pain Reports in press
44. Kaptchuk TJ, Miller FG (2018) Open label placebo: can honestly prescribed placebos evoke meaningful therapeutic benefits? Br Med J 363:3

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Authors and Affiliations

Henriët van Middendorp\textsuperscript{1} · Anneleen Berende\textsuperscript{2,3} · Fidel J. Vos\textsuperscript{2,4} · Hadewych H. M. ter Hofstede\textsuperscript{2} · Bart Jan Kullberg\textsuperscript{2} · Andrea W. M. Evers\textsuperscript{1,5}

\textsuperscript{1} Health, Medical and Neuropsychology Unit, Faculty of Social and Behavioural Sciences, Institute of Psychology, Leiden University, PO Box 9555, 2300 RB Leiden, The Netherlands

\textsuperscript{2} Department of Medicine, Radboud Center for Infectious Diseases, Radboud University Medical Center, Nijmegen, The Netherlands

\textsuperscript{3} Gelre Ziekenhuizen, Apeldoorn, The Netherlands

\textsuperscript{4} Sint Maartenskliniek, Nijmegen, The Netherlands

\textsuperscript{5} Department of Psychiatry, Leiden University Medical Center, Leiden, The Netherlands